by | Oct 17, 2024 | Lupus Foundation of America, News & Events
Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy for lupus nephritis (LN). This follows the clinical trial hold placed by the U.S. Food and Drug Administration (FDA), which came after Kezar...
by | Oct 16, 2024 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) cleared the investigational new drug application for Cullinan Therapeutics’ CLN-978 for the treatment of systemic lupus erythematosus (SLE). Researchers will initiate a global Phase 1 trial to evaluate the safety of CLN-978...
by | Oct 15, 2024 | Lupus Foundation of America
This Hispanic Heritage Month, we celebrate the strength, culture, and contribution of the Hispanic and Latino communities across the country. As we celebrate these vibrant communities, it’s also important to recognize the profound ways lupus affects them differently....
by | Oct 9, 2024 | Lupus Foundation of America, News & Events
Neuropsychiatricsystemic lupus erythematosus (NPSLE), or central nervous system lupus, can be challenging to diagnose because of the variability in how it manifests itself in different people. In a new study, researchers reviewed recent advances in NPSLE from a...
by | Oct 8, 2024 | Lupus Foundation of America
Each year, Medicare beneficiaries are given the opportunity to select a new plan for the upcoming year during the Open Enrollment Period. This year, Open Enrollment begins on October 15 and will run until December 7, 2024.New this year: Medicare Part D prescription...
by | Oct 7, 2024 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Kezar Life Sciences’ zetomipzomib, an investigational therapy for lupus nephritis (LN). This comes after Kezar Life Sciences reported they had voluntarily ended enrollment and dosage of their...
